Overview

• Ten patients aged 1 to 24 received a single inner-ear AAV-OTOF injection at five hospitals in China.
• Measurable hearing recovery began within one month for most participants.
• At six months, average pure-tone thresholds improved from 106 decibels to 52 decibels across all patients.
• No serious adverse events occurred; the most common side effect was a temporary drop in neutrophil counts.
• Researchers have started extended follow-up to evaluate durability and plan to adapt the approach to other deafness genes like GJB2 and TMC1.